For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| General and administrative | 1,249,961 | 1,431,157 | 1,219,018 | |
| Research and development | 345,969 | 402,417 | 1,260,051 | |
| Depreciation and amortization | 37,240 | 40,369 | 39,980 | |
| Total operating expenses | 1,633,170 | 1,873,943 | 2,519,049 | |
| Loss from operations | -1,633,170 | -1,873,943 | -2,519,049 | |
| Other income | - | - | 0 | |
| Interest (expense) income, net | -303 | 274 | -132 | |
| Total other (expense) income | -303 | 274 | -132 | |
| Net loss before income taxes | -1,633,473 | -1,873,669 | -2,519,181 | |
| Income tax expense | - | - | 0 | |
| Net loss | -1,633,473 | -1,873,669 | -2,519,181 | |
| Less deemed dividend on inducement of warrants | - | 1,513,449 | - | |
| Net loss attributable to shareholders | - | -3,387,118 | - | |
| Foreign currency translation | -7,018 | -7,414 | 24,473 | |
| Comprehensive loss | -1,640,491 | -3,394,532 | -2,494,708 | |
| Basic EPS | -1.08 | -10.81 | -0.97 | |
| Diluted EPS | -1.08 | -10.81 | -0.97 | |
| Basic Average Shares | 1,510,401 | 313,242 | 2,595,728 | |
| Diluted Average Shares | 1,510,401 | 313,242 | 2,595,728 | |
Enveric Biosciences, Inc. (ENVB)
Enveric Biosciences, Inc. (ENVB)